We are seeking people with a condition, Diabetic Kidney Disease (DKD), to participate in a study. The study is testing a new way of treating DKD with an drug called "propagermanium".
Propagermanium is an experimental treatment in Australia. This means it has not been approved by the Therapeutic Goods Administration for treatment of DKD in Australia however it has been licensed for use in Japan since 1994 for the treatment of chronic hepatitis B infection.
The purpose of this trial is to test if propagermanium is safe and effective in treating participants with DKD who are on a daily dose of 300 mg irbesartan when compared to placebo.
This study will determine how safe and effective the drug is by:
- monitoring symptoms that you may experience while on the study;
- measuring levels of albuminuria and your kidney function during the course of the study;
- measuring the levels of propagermanium and irbesartan that enters your blood and urine.
Primary biliary cholangitis (PBC) is a chronic disease in which the bile ducts in your liver are slowly destroyed. Human studies have shown that seladelpar may be useful for treating the signs and symptoms of PBC and lower alkaline phosphatase (AP) level and decrease itching.
The purpose of this research is to evaluate the safety and effectiveness of an investigational drug, seladelpar, in treating patients with PBC.
The purpose of this study is to find out if Cabozantinib in combination with Atezolizumab is effective in treating liver cancer (hepatocellular carcinoma) compared to Sorafenib alone in people who have not received prior treatment.
This study will also examine how well people with liver cancer who have not received prior treatment tolerate Cabozantinib alone, and how well it works in treating their cancer.
We are looking for people with Crohn's Disease to participate in a study to determine the safety and effictiveness of a new study medication, guselkumab.
Guselkumab is made in the laboratory and is a fully human monoclonal antibody. An antibody is something that targets and kills foreign objects in the body - in this case, small proteins that are released by cells and affect the behaviour of other cells. This antibody, guselkumab, recognizes and blocks a specific small protein, IL-23, which is important in immune and inflammatory processes.
The main aim of this study is to investigate the effectiveness of a new drug (ANAVEX 2-73) in treating early Alzheimer’s disease. Two clinical studies investigating use of ANAXVEX 2-73 in human subjects have been completed and have shown positive outcomes in cognition, such as memory, attention, speed of processing and reasoning and problem solving.
The current study extends on previous findings to further investigate the effect of this drug (including at varying dose levels) on cognitive and functional outcomes – the former being various aspects of thinking abilities and the latter being independence in completion of daily activities.
The purpose of this research study is to compare the effects of the study drug, PF-06687234, with a placebo while also being treated with infliximab to find out which is better for treating Ulcerative Colitis (UC).
The study drug, PF-06687234 has two proteins that are connected to each other. One protein seeks out and attaches to areas of inflammation (for example the colon in UC). The second protein works to “calm down” the immune system in inflamed areas such as the colon, in UC. A placebo looks like the study drug but does not contain any active drug. Researchers use a placebo to see if the study drug works better or is safer than not taking anything.
PF-06687234 is an experimental drug which means that it is not an approved treatment for UC in Australia.
The purpose of this study is to see if guselkumab and golimumab when used together is safe and effective for treating participants with moderately to severely active ulcerative colitis (UC).
Guselkumab has been approved in the USA, the European Union (EU), Canada, and several other countries, including the Australian health authority (Therapeutic Goods Administration), for the treatment of adult patients with moderate to severe plaque psoriasis. In addition, guselkumab is being studied for the treatment of psoriatic arthritis, Crohn’s disease, and paediatric psoriasis.
Golimumab has been approved in countries worldwide, including the Therepeutic Goods Administration, for the indications of moderately to severely active ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
The primary purpose of your participation in this study is not to treat you for your condition but to help answer the following research question: How mirikizumab compares with placebo in helping patients with UC?
Mirikizumab is an experimental treatment. This means that it is not an approved treatment for UC in Australia, by the Therapeutic Goods Administration.